IL37 and type 2 diabetes mellitus: Telikani et al. found that sitagliptin, in combination with vitamin D3, up-regulated FoxP3 expression and IL-37 and downregulated IFN-γ, IL-17, and IL-21 production in vivo in patients with T2DM [26].